Symbicort® COPD (budesonide/formoterol)
Symbicort® Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist
Symbicort® Turbohaler® (200/6 µg and 400/12 µg) and Symbicort® pMDI (200/6 µg) are indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy. 1-3
Symbicort® pMDI is to be used in the treatment of COPD and is not approved within the EU for the treatment of asthma. Symbicort® pMDI is not to be used as a reliever medication, and consequently is not suitable for use as maintenance and reliever therapy (i.e. SMART).
Symbicort pMDI can be used with or without a spacer. When a spacer is required, the AeroChamber Plus Flow Vu or AeroChamber Plus spacers are recommended.
Symbicort Turbohaler 100/6 is not licensed in COPD.